Skip to main content
Clinical Trials/NCT02156817
NCT02156817
Completed
N/A

Neurophysiologic Maturation Index: NEMO Project for Late Preterm Infants

Brown University3 sites in 2 countries26 target enrollmentMarch 1, 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Neurophysiologic Maturation
Sponsor
Brown University
Enrollment
26
Locations
3
Primary Endpoint
Magnitude of variance, R square
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

Late preterm infants contribute to significant neonatal intensive care unit health care resource utilization because of their sheer numbers. Determinants of the length of hospitalization (LOH) in this population are understudied. Gestational age (GA) is used most commonly as a predictor for LOH but there are many limitations including inaccurate dating and morbidities of prematurity which at least partly related to neurophysiological immaturity. The latter can be assessed by amplitude integrated electroencephalogram (aEEG, a simplified 5 lead EEG), and possibly by heart rate variability (HRV) and respiratory variability (RV). All 3 are non-invasive tests that can be done at the bedside. Our study hypothesis is to determine if neurophysiologic maturation as assessed by aEEG, HRV and RV within 24-96 hours following birth improves the correlation between gestational age and length of hospitalization compared to gestational age alone.

Registry
clinicaltrials.gov
Start Date
March 1, 2014
End Date
June 2, 2017
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Birju A. Shah, MD MPH

Associate Professor of Pediatrics

University of Oklahoma

Eligibility Criteria

Inclusion Criteria

  • Gestational age of 340-346 weeks by Obstetric criteria (presence of a sure LMP or sonogram performed in the first trimester, or agreement between LMP and a sonogram performed between the first trimester and 20 weeks)
  • Admitted to a NICU of a participating institution
  • Post-natal age less than 96 hours

Exclusion Criteria

  • Major congenital anomaly/genetic anomaly
  • Growth restriction (birth weight \< 10%, Fenton growth curves)
  • Unsure obstetric dating (e.g., absence of a sure LMP without a sonogram, earliest sonogram performed after 20 weeks without a sure LMP, or discrepancy between LMP and sonogram)
  • Exposure to medications within the preceding 12 hrs which may affect CNS function (e.g., fentanyl, morphine, midazolam)
  • Neonatal seizures
  • Neonatal abstinence syndrome secondary to in-utero exposure to narcotics, methadone etc, or at high risk for development of abstinence
  • Hypoxia-ischemia defined as the combination of fetal acidemia (cord gas or blood gas within 1 hour of birth: pH ≤ 7.15 or BE ≥ -10mEq/L), need for resuscitation at birth (PPV ± chest compressions or medications), and evidence of encephalopathy (Stage 1, 2 or 3 Sarnat). Stage 1 encephalopathy will be defined based on the level of consciousness which is characterized by a hyper-alert state, apparent alertness, and irritability. In the absence of a cord or early post-natal blood gas, there must be a history of a perinatal event which may have compromised oxygenation or blood flow to the fetus.
  • Infants who are expected to be on mechanical (via an endotracheal tube) or high frequency ventilation for the first 96 hours after birth.
  • Inability to obtain the informed consent

Outcomes

Primary Outcomes

Magnitude of variance, R square

Time Frame: 2 years

linear regression model: LOH = intercept + b1GA + b2aEEG + b3HRV + b4RV + error term; b1 - b4 represents the weight of each variable to explain the variance of the equation (R2), GA is gestational age, aEEG is amplitude integrated EEG, HRV is heart rate variability, RV is respiratory variability, LOH is length of hospital stay

Secondary Outcomes

  • Amplitude integrated electroencephalogram (aEEG)(participants will be followed for the duration of hospital stay, an expected average of 5 weeks)
  • Respiratory variability (RV)(participants will be followed for the duration of hospital stay, an expected average of 5 weeks)
  • Heart rate variability (HRV)(participants will be followed for the duration of hospital stay, an expected average of 5 weeks)

Study Sites (3)

Loading locations...

Similar Trials